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ABSTRACT
BACKGROUND: Despite large disparities in the burden of chronic liver disease, data 
on hepatitis C virus (HCV) infection among American Indians (AIs) are lacking. We 
reviewed hepatitis C diagnoses in 35,712 AI/AN primary care patients. MAIN FINDINGS: 
At least one HCV-associated ICD-9 code was recorded in 251 (1%) patients between 
October 1, 2001 and September 30, 2003. An HCV enzyme-linked immunoassay (HCV-
EIA) was sent in 209 (83.0%); 206/209 (99%) were positive. Con#rmatory testing was 
performed in 144/206 (70%) HCV-EIA positive patients; HCV infection was con#rmed 
in 144 (100%). In the 90/144 (63%) charts with risk factor documentation, injection 
drug use was the most common risk factor (61/90, 68%). De#ciencies were present in 
hepatitis B and HIV testing, and hepatitis A and B vaccination. PRINCIPAL CONCLUSIONS: 
Improvements in laboratory workup of HCV and co-infections, risk factor ascertainment 
and documentation, and adult vaccination are needed to address HCV e"ectively in this 
population.
Key Words: Community/public health; Infectious Disease; Special population: Native 
American/First Nations; Primary Care Issues
INTRODUCTION
Chronic liver disease (CLD) represents a major area of health disparity for American Indians and 
Alaska Natives (AI/ANs), in whom the age-adjusted CLD mortality rate is more than twice that of 
other racial groups. 1 In a recent Centers for Disease Control and Prevention (CDC)/Indian Health 
Service (IHS) study, approximately 5.5% of all adult AI/AN users at two IHS sites had CLD, of which 
approximately one quarter was caused by hepatitis C or hepatitis C plus alcohol abuse. 2
In the United States, hepatitis C virus (HCV) infection accounts for approximately 40% of chronic 
liver disease (CLD). 3,4 Major risk factors for HCV infection include injection drug use (IDU), receipt of 
clotting factors prior to 1987, and receipt of blood or solid organs before 1992. 5-9 Given the burden 
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of CLD in AI/AN populations, determining gaps in HCV diagnosis and disease management in AI/ANs 
is essential to improving outcomes and allocating resources for prevention and treatment. 
We undertook this study to: 1) characterize diagnoses of HCV infection in a well-de#ned primary 
care IHS AI/AN population; 2) determine the completeness of HCV-related patient evaluation and 
treatment; and 3) identify aspects of HCV-related patient care in need of improvement.
METHODS
Human Subjects:  This project was reviewed/approved by institutional review boards of the Indian 
Health Service, Centers for Disease Control and Prevention, and the University of New Mexico Health 
Sciences Center.  Approval was also obtained from the involved IHS Service Unit Health Boards.   
Setting: We performed our study at two IHS clinical facilities (service units) in the southwestern 
United States. 
Subjects: Using the IHS electronic medical record system, we searched for patients who met all 
of the following criteria: 1) The patient was an AI/AN aged 18 years or older as of the beginning of 
the study period (October 1, 2001 through September 30, 2003); (2) the patient had > 1 in-patient 
admission(s) or out-patient visit(s) to an IHS facility during the study period; (3) for at least one 
admission or visit during the study period, or within three years prior to the beginning of the study 
period, the patient was assigned a HCV-related International Classi#cation of Diseases, Version 9 
(ICD-9) diagnosis (Appendix A). We considered con#rmed case-patients to be those whose laboratory 
results indicated infection with HCV, de#ned as: (1) HCV enzyme immunoassay (EIA) antibody 
positive plus one or more con#rmatory test (recombinant immunoblot assay [RIBA] or HCV nucleic 
antibody test [NAT]) positive; or (2) In the absence of con#rmatory testing, EIA antibody positive with 
signal-to-cuto" ratio ≥ 3.8.  
We extracted the following patient information by electronic medical record and paper chart 
review:  
Demographic data:  date of birth, sex, and tribal a!liation.
HCV laboratory tests: HCV EIA, including signal-to-cuto" ratio (if available), HCV antibody RIBA, 
HCV genotype, HCV polymerase chain reaction (PCR) qualitative, and HCV ribonucleic acid (RNA) 
quantitative.
Past or present co-infections: hepatitis A, B, and D antibodies; HIV antibody. 
Additional tests:  alanine aminotransferase [ALT], liver ultrasound and computerized tomography, 
liver biopsy. 
Additional CLD-related diagnoses or co-morbid conditions: alcoholic liver disease, non-alcoholic 
steatohepatitis, other non-infectious causes of hepatitis and/or chronic liver disease, diabetes 
mellitus, hepatocellular carcinoma. 
Treatment and vaccination history: HCV treatment, hepatitis A/B vaccination history.
Risk factors for HCV infection:  history of injecting drug use, blood or blood product transfusion or 
whole organ transplantation prior to 1992, and receipt of clotting factors prior to 1987.
Data Analysis: Analysis was performed using Epi-Info 3.3.2 (Centers for Disease Control and 
Prevention, Atlanta, Georgia), Excel (Microsoft, Redmond, Washington) and JMP 5.0 (SAS Institute, 
Cary, North Carolina). Continuous variables were tested using the t-test for means with unequal 
sample sizes and assumption of equal variance, and categorical variables were analyzed using the 
chi-squared contingency test. We assumed an alpha level of less than or equal to .05 to be signi#cant. 
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RESULTS
HCV Diagnostic Testing: We identi#ed 35,712 unique patients ≥ 18 years of age at the beginning 
of the study period who had at least one in-patient admission(s) or out-patient visit(s) to an IHS 
facility in one of the two service units during the study period. An electronic medical records search 
yielded a total of 323 patients (1%) with at least one HCV-associated ICD-9 diagnosis.  Of these 
patients, 30/323 (9.3%) had neither mention of hepatitis C in their chart nor any HCV testing and 
were judged to be coding errors. Paper charts were available and reviewed on 251/293 (86%) of 
charts without coding errors. 
Among these 251 fully-reviewed patient charts, an HCV EIA was performed and recorded in 
209 (83%). The remaining 42 (17%) patient charts mentioned HCV, but no diagnostic testing was 
recorded. Hepatitis C virus EIA was positive in 206/209 (99%). Hepatitis C virus past or present 
infection was con#rmed in 144 (70%) of the 206 patients with a positive EIA: 94 (65%) by positive 
nucleic acid test (NAT) alone; 15 (10%) by positive recombinant immunoblot assay (RIBA) alone; and 
35 (24%) by both RIBA and PCR.  No patients had a positive EIA but negative con#rmatory test. The 
rest of our analysis focused on the 144 patients with con#rmed past or current HCV infection. 
Demographics: Patients with con#rmed past or current HCV infection were 54% male. Mean age 
????????????????????????????????????????????????????????????????????????????????????????? ????????
was 39.8 years among men and 42.4 years among women (t-test for means p = .09). Patients were 
a!liated with 57 di"erent American Indian tribes. 
Risk Factors: CV risk factor data were recorded in the charts of 90/144 (63%) con#rmed patients, 
among whom the majority reported injection drug use (Figure 1).
Figure 1. Risk factors among 144 AI/AN patients with con#rmed hepatitis C infection at two IHS 
service units, 2001-2003
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Clinical Data: Clinical data are summarized in Table 1. 
Table 1. Clinical Characteristics of 144 AI/AN Patients with Con#rmed Hepatitis C Infection at 
Two IHS Service Units, 2001-2003
Characteristic Result
Co-Morbid Medical Conditions
Alcoholic liver disease 17/125 (14%)
Alcohol use ever 113/125 (90%)
Alcohol use documented when most recently asked 47/125 (38%)
Non-alcoholic steatohepatitis or non-alcoholic fatty 
liver disease
3/51 (6%)
Diabetes mellitus 21/136 (15%)
General Laboratory Testing
Alanine transaminase, IU/L (n = 126) Range 123 - 1313 IU/L; median 68 IU/L
Infectious Disease Testing
HCV genotype
1/1a/1b/1c 38/56 (68%)
2/2a/2b/2c 9/56 (16%)
3/3a/3b 8/56 (14%)
HCV RNA, IU/ml (n = 75) Range 0 - 4,510,000 IU/ml; 
median 182,000 IU/ml 
Co-infections:
HIV 4/65 (6.2%)
HBV
Total anti-core antibody 1/32 (3%)
IgM anti-core antibody 0/38 (0%)
HBV surface antibody (HBsAb) 13/71 (18%)
HBV surface antigen (HBsAg) 2/89 (2%)
Other Diagnostic Testing
Liver ultrasound performed 31/144 (22%)
Liver CT performed 4/144 (3%)
Liver biopsy performed 17/144 (12%)
Vaccination
Hepatitis A vaccination documented 43/142 (30%)
Hepatitis B vaccination documented 54/142 (38%)
Treatment: Initiation of combination therapy (ribavirin and interferon) for HCV infection was 
documented in 37/144 (26%) patients. 
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DISCUSSION
This is the #rst report of HCV diagnoses in a well-de#ned population of AI/ANs outside of Alaska 
to include information on hepatitis C treatment and follow-up,2,10-12 and points to several areas in 
which care for HCV-infected patients might be improved within the IHS healthcare delivery system in 
this region.
Our results con#rm that an important co-morbidity associated with worse clinical outcomes in 
HCV-infected patients, alcohol use, was common in this AI/AN population.  Expanded resources for 
alcohol counseling and treatment are critically needed in this population.
We found that risk factors were not documented in the charts of 38% of patients with con#rmed 
HCV infection (Figure 1). A systematic, standardized approach to more complete risk factor 
assessment and documentation for all AI/AN patients seeking care in these settings would ensure 
that more high-risk patients are appropriately tested for HCV and receive risk reduction counseling. 
We found many of the steps recommended in evaluation and follow up of HCV-antibody 
positive persons 6,13 were not clearly documented, and thus modi#cations to clinical protocols for 
HCV-positive patients would be bene#cial.  First, we found that con#rmatory HCV testing was not 
obtained in 30% of patients with a positive HCV EIA.  In an additional 10% of patients, only RIBA 
was used to con#rm HCV antibody presence, and no further test to distinguish past from current 
infection was documented.  A standardized protocol to automatically perform con#rmatory HCV 
testing on EIA-positive patients would help ensure diagnostic accuracy so that patients with current, 
active HCV infections receive appropriate care promptly and those that are HCV-RNA negative avoid 
unnecessary medical interventions.  
Persons with con#rmed current hepatitis C infection should be evaluated for the presence 
and extent of chronic liver disease.  We found documentation of the recommended ALT test in 
88% of patients, a quantitative HCV test in 52%, and genotype in 39%.  Only 12% of patients had 
a documented liver biopsy, which is helpful in determining stage of chronic liver disease with 
presence of scarring. 13 Similarly, our results indicate that testing for co-infections with HIV and HBV 
was incomplete.  Since injection drug use, the most commonly documented risk factor in this and 
other HCV patient populations, is also a risk factor for HIV and HBV infection, it is important to test 
appropriately for these infections as well.  Co-infection may dramatically a"ect the clinical course of 
HCV, as well as treatment options. 13,14 
HCV treatment was documented to have been initiated in 37/144 (26%) patients.  Hepatitis C 
treatment options for AI/AN people have increased, so treatment may have become more available 
since the time period included in our data set. Although currently recommended combination 
therapy with ribavirin and interferon is generally not available as standard treatment at most 
IHS facilities, treatment options for this population are enhanced by an ongoing collaboration 
between IHS and the University of New Mexico Health Sciences Center’s Project ECHO (Extension for 
Community Healthcare Outcomes). 15,16 
Lastly, vaccination against HAV and HBV was documented in only a minority of charts. Although 
our data may underestimate actual HAV/HBV immunization coverage in this population since 
patients may have been vaccinated elsewhere, the overall absence of documentation of HAV or HBV 
immunity is problematic, and immunization guidelines should be added to the protocols suggested 
above.   
Limitations of this investigation include the fact that we established HCV infection diagnoses 
retrospectively based on ICD-9 coding, so patients with HCV infection had to be identi#ed as such 
by the IHS health system to be counted.  Therefore, our results are not a measure of the underlying 
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prevalence of HCV infection in the population, which is certain to be higher than the rate of 
diagnosed HCV infections that we found. Our investigation evaluated medical chart-documented 
diagnoses, and does not re$ect the entirety of hepatitis C infection in the AI/AN population, which 
has well-documented disparities in CLD mortality 1,2 In addition, although using ICD-9 codes is a 
convenient and cost-e"ective method for looking at diagnoses in large populations, this approach 
is also subject to limitations, such as describing complex human diseases with a limited number of 
speci#c codes. 17,18 Because we depended upon narrative chart notes to determine risk factors, data 
regarding risks for HCV infection are likely to be incomplete.  Finally, this study is speci#c to patients 
accessing a single health care system and may not apply to other AI/AN and non-AI/AN populations 
and health systems.
CONCLUSIONS
In this population of 35,712 AI/AN adults using two IHS facilities, we identi#ed by medical 
record review over 250 patients with possible, and 144 with con#rmed, HCV infections.  There were 
signi#cant gaps in documentation of HCV-associated risk factors, laboratory con#rmation of HCV 
infections, screening and testing for co-morbid conditions, vaccination, and recommended follow 
up for evaluation of chronic liver disease and possible treatment. Comprehensive management 
of HCV infections in this population with noted health disparities will require more standardized 
laboratory workup of both HCV and co-infections, improvements in risk factor ascertainment and 
documentation, and improved adult vaccination. 
Disclaimers  
(1) Use of trade names is for informational purposes only and does not constitute endorsement by 
the Centers for Disease Control and Prevention or the Indian Health Service.
(2) The #ndings and conclusions of this report are those of the authors and do not necessarily 
represent the views of the Centers for Disease Control and Prevention or the Indian Health 
Service.
Appendix A: Hepatitis C-associated ICD-9 Codes
571.4 Chronic hepatitis
571.40 Chronic hepatitis, unspeci#ed
571.41 Chronic persistent hepatitis
571.49 Other chronic hepatitis: Active, aggressive recurrent hepatitis
 Excludes: viral hepatitis (acute, chronic) (070.0-070.9)
070.41 Acute or unspeci#ed hepatitis C with hepatic coma
070.44 Chronic hepatitis C with coma
070.51 Acute or unspeci#ed hepatitis C without hepatic coma
070.54 Chronic hepatitis C without hepatic coma
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